MX2016003530A - Proteina de fusion. - Google Patents
Proteina de fusion.Info
- Publication number
- MX2016003530A MX2016003530A MX2016003530A MX2016003530A MX2016003530A MX 2016003530 A MX2016003530 A MX 2016003530A MX 2016003530 A MX2016003530 A MX 2016003530A MX 2016003530 A MX2016003530 A MX 2016003530A MX 2016003530 A MX2016003530 A MX 2016003530A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion protein
- nbp
- p75ntr
- pain
- immunoglobulin
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 abstract 3
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 abstract 3
- 102000019507 neurotrophin binding proteins Human genes 0.000 abstract 3
- 108091016216 neurotrophin binding proteins Proteins 0.000 abstract 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2807—Headache; Migraine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Epidemiology (AREA)
Abstract
La presente invención se refiere a una proteína de fusión de p75NTR proteína deunión a neurotrofina (NBP)-Fc, que comprende una porción de p75NTR(NBP) y una porción de inmunoglobulina; en ciertas modalidades, la proteína de fusión p75NTR(NBP)-Fc es para uso en el tratamiento de dolor y/o un síntoma de dolor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1316592.3A GB201316592D0 (en) | 2013-09-18 | 2013-09-18 | Fusion protein |
| PCT/GB2014/052833 WO2015040398A1 (en) | 2013-09-18 | 2014-09-18 | Fusion protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016003530A true MX2016003530A (es) | 2016-10-13 |
| MX375514B MX375514B (es) | 2025-03-06 |
Family
ID=49552839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016003530A MX375514B (es) | 2013-09-18 | 2014-09-18 | Proteína de fusión. |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US9873728B2 (es) |
| EP (1) | EP3046934B1 (es) |
| JP (3) | JP6681834B2 (es) |
| KR (1) | KR102205633B1 (es) |
| CN (1) | CN105873943B (es) |
| AU (1) | AU2014322842B2 (es) |
| CA (1) | CA2924410C (es) |
| CY (1) | CY1121347T1 (es) |
| DK (1) | DK3046934T3 (es) |
| EA (1) | EA037416B1 (es) |
| ES (1) | ES2714694T3 (es) |
| GB (1) | GB201316592D0 (es) |
| HR (1) | HRP20190434T1 (es) |
| HU (1) | HUE043273T2 (es) |
| IL (1) | IL244588B (es) |
| LT (1) | LT3046934T (es) |
| MX (1) | MX375514B (es) |
| NZ (1) | NZ718044A (es) |
| PL (1) | PL3046934T3 (es) |
| PT (1) | PT3046934T (es) |
| RS (1) | RS58463B1 (es) |
| SG (1) | SG11201602068QA (es) |
| SI (1) | SI3046934T1 (es) |
| SM (1) | SMT201900122T1 (es) |
| TR (1) | TR201903490T4 (es) |
| WO (1) | WO2015040398A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2637341T3 (es) | 2012-03-14 | 2017-10-11 | Levicept Ltd. | Proteína de unión a neurotrofina P75NTR para su utilización terapéutica |
| GB201316592D0 (en) | 2013-09-18 | 2013-10-30 | Levicept Ltd | Fusion protein |
| GB201412748D0 (en) | 2014-07-17 | 2014-09-03 | Levicept Ltd | Therapeutic use of P75NTR neurotrophin binding protein |
| GB201504691D0 (en) * | 2015-03-19 | 2015-05-06 | Levicept Ltd | Fusion protein |
| EP3711772A1 (en) | 2019-03-20 | 2020-09-23 | Oslo Universitetssykehus HF | Recombinant proteins and fusion proteins |
| CN113456799A (zh) * | 2020-12-25 | 2021-10-01 | 苏州澳宗生物科技有限公司 | 一种p75ECD在制备用于调节疼痛的药物中的应用 |
| CN112851794B (zh) * | 2021-02-04 | 2023-05-23 | 苏州铂维生物科技有限公司 | 一种基于cd271的抗原表位及其应用 |
| US11608371B1 (en) | 2021-10-21 | 2023-03-21 | Petmedix Ltd | Therapeutic molecules |
| KR20240099321A (ko) * | 2021-10-21 | 2024-06-28 | 펫메딕스 리미티드 | P75ntr의 세포외 도메인을 포함하는 단백질 |
| IL322604A (en) * | 2023-02-08 | 2025-10-01 | Levicept Ltd | Fusion protein |
| CN120712277A (zh) * | 2023-02-09 | 2025-09-26 | 佩特迈迪有限公司 | 包含p75神经营养因子受体(p75ntr)胞外结构域变体的治疗分子 |
| GB202307936D0 (en) * | 2023-05-26 | 2023-07-12 | Levicept Ltd | Fusion protein |
| GB202400055D0 (en) | 2024-01-03 | 2024-02-14 | Tribune Therapeutics Ab | Use of ccn domain-containing proteins for the treatment of disease |
| WO2025181486A1 (en) | 2024-02-27 | 2025-09-04 | Levicept Limited | Process for manufacturing of glycosylated p75ntr-fc fusion protein |
| WO2025184422A1 (en) * | 2024-02-27 | 2025-09-04 | Levicept Ltd | Fusion protein and uses thereof |
| WO2025181485A1 (en) | 2024-02-27 | 2025-09-04 | Levicept Limited | P75 neurotrophin receptor-fc fusion protein for use in pain therapy |
| WO2025262427A1 (en) | 2024-06-19 | 2025-12-26 | Levicept Limited | Injectable formulation |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
| FR2686900B1 (fr) * | 1992-01-31 | 1995-07-21 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant. |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| JP2007531707A (ja) | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ， インコーポレイテッド | ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変 |
| WO2006079176A1 (en) * | 2005-01-28 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
| WO2007026567A1 (ja) | 2005-08-30 | 2007-03-08 | National University Corporation Chiba University | ｐ７５ＮＴＲ阻害剤を有効成分として含有する鎮痛剤 |
| AU2006326870A1 (en) * | 2005-12-22 | 2007-06-28 | Apollo Life Sciences | Transdermal delivery of pharmaceutical agents |
| GB0717985D0 (en) * | 2007-07-20 | 2007-10-24 | Asterion Ltd | Growth hormone fusion proteins |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| US20100061981A1 (en) | 2008-08-15 | 2010-03-11 | The Salk Institute For Biological Studies | p75NTR MEDIATES EPHRIN-A REVERSE SIGNALING |
| WO2010117786A1 (en) * | 2009-03-30 | 2010-10-14 | Mount Sinai School Of Medicine Of New York University | Influenza virus vaccines and uses thereof |
| CA2777717C (en) * | 2009-10-15 | 2021-05-25 | Genentech, Inc. | Chimeric fibroblast growth factors with altered receptor specificity |
| WO2011068993A1 (en) * | 2009-12-02 | 2011-06-09 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life of fc fusion proteins. |
| JP5631131B2 (ja) * | 2010-09-17 | 2014-11-26 | 株式会社日本マイクロニクス | 通電試験用プローブ及びプローブ組立体 |
| CN102233128B (zh) * | 2010-11-26 | 2013-04-17 | 王延江 | 一种p75NTR-ECD在防治阿尔茨海默病药物中应用 |
| ITRM20110024A1 (it) | 2011-01-24 | 2012-07-25 | Consiglio Nazionale Ricerche | Uso di antagonisti del recettore p75ntr e/o di agonisti del recettore trka per il trattamento delle malattie infiammatorie croniche. |
| US20130078250A1 (en) * | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
| TWI476001B (zh) * | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Ｆｃ融合蛋白及其用途 |
| CN102586313A (zh) | 2012-03-05 | 2012-07-18 | 中国人民解放军第三军医大学野战外科研究所 | p75NTR-ED-Fc融合蛋白的制备方法及其在损伤中枢神经再生与功能恢复中的应用 |
| ES2637341T3 (es) | 2012-03-14 | 2017-10-11 | Levicept Ltd. | Proteína de unión a neurotrofina P75NTR para su utilización terapéutica |
| EP2674439B1 (en) * | 2012-06-13 | 2017-02-01 | Rottapharm Biotech S.r.l. | Anti-TrkA antibodies, derivatives and uses thereof |
| GB201316592D0 (en) | 2013-09-18 | 2013-10-30 | Levicept Ltd | Fusion protein |
| GB201412748D0 (en) * | 2014-07-17 | 2014-09-03 | Levicept Ltd | Therapeutic use of P75NTR neurotrophin binding protein |
| GB201504691D0 (en) | 2015-03-19 | 2015-05-06 | Levicept Ltd | Fusion protein |
-
2013
- 2013-09-18 GB GBGB1316592.3A patent/GB201316592D0/en not_active Ceased
-
2014
- 2014-09-18 PT PT14772194T patent/PT3046934T/pt unknown
- 2014-09-18 EA EA201690469A patent/EA037416B1/ru unknown
- 2014-09-18 MX MX2016003530A patent/MX375514B/es active IP Right Grant
- 2014-09-18 LT LTEP14772194.8T patent/LT3046934T/lt unknown
- 2014-09-18 DK DK14772194.8T patent/DK3046934T3/en active
- 2014-09-18 HU HUE14772194A patent/HUE043273T2/hu unknown
- 2014-09-18 TR TR2019/03490T patent/TR201903490T4/tr unknown
- 2014-09-18 CA CA2924410A patent/CA2924410C/en active Active
- 2014-09-18 KR KR1020167010006A patent/KR102205633B1/ko active Active
- 2014-09-18 US US15/022,505 patent/US9873728B2/en active Active
- 2014-09-18 HR HRP20190434TT patent/HRP20190434T1/hr unknown
- 2014-09-18 JP JP2016543457A patent/JP6681834B2/ja active Active
- 2014-09-18 EP EP14772194.8A patent/EP3046934B1/en active Active
- 2014-09-18 CN CN201480060027.8A patent/CN105873943B/zh active Active
- 2014-09-18 SG SG11201602068QA patent/SG11201602068QA/en unknown
- 2014-09-18 RS RS20190259A patent/RS58463B1/sr unknown
- 2014-09-18 SI SI201431067T patent/SI3046934T1/sl unknown
- 2014-09-18 PL PL14772194T patent/PL3046934T3/pl unknown
- 2014-09-18 ES ES14772194T patent/ES2714694T3/es active Active
- 2014-09-18 NZ NZ718044A patent/NZ718044A/en unknown
- 2014-09-18 AU AU2014322842A patent/AU2014322842B2/en active Active
- 2014-09-18 SM SM20190122T patent/SMT201900122T1/it unknown
- 2014-09-18 WO PCT/GB2014/052833 patent/WO2015040398A1/en not_active Ceased
-
2016
- 2016-03-14 IL IL244588A patent/IL244588B/en active IP Right Grant
-
2017
- 2017-12-15 US US15/844,022 patent/US10988526B2/en active Active
-
2019
- 2019-03-08 CY CY20191100281T patent/CY1121347T1/el unknown
- 2019-10-29 JP JP2019195922A patent/JP2020062011A/ja active Pending
-
2021
- 2021-03-24 US US17/211,362 patent/US20210238256A1/en active Pending
-
2022
- 2022-02-10 JP JP2022019327A patent/JP7357088B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016003530A (es) | Proteina de fusion. | |
| AR132864A2 (es) | UN ANTICUERPO QUE SE UNE ESPECÍFICAMENTE A a-SINUCLEÍNA HUMANA, UN ANTICUERPO HUMANIZADO, UNA FORMULACIÓN FARMACÉUTICA QUE COMPRENDE EL ANTICUERPO, Y LA UTILIZACIÓN DEL ANTICUERPO | |
| MX2024006565A (es) | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. | |
| CL2019000261A1 (es) | Polipéptidos modificados y usos de los mismos. | |
| CO2018009995A2 (es) | Proteínas de unión y métodos de uso de las mismas | |
| EA201690314A1 (ru) | Анти-garp-белок и его применения | |
| UY36021A (es) | Proteìnas fc multimèricas | |
| BR112017011932A2 (pt) | ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso? | |
| UY35417A (es) | Anticuerpos dirigidos contra il-33 y sus usos. | |
| MX2016009555A (es) | Proteinas de union y metodos para utilizarlas. | |
| MX374811B (es) | Anticuerpos anti-tau y métodos de uso. | |
| BR112013024574A2 (pt) | polipeptídeo, uso, método de tratamento de indivíduos portadores de doenças e método de tratamento de indivíduos que possuem doenças com um polipeptídeo | |
| MX380520B (es) | Anticuerpos receptores de antitransferina y métodos de uso. | |
| EA201691214A1 (ru) | Антитела к cd33 и иммуноконъюгаты | |
| BR112014026740A8 (pt) | anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
| GT201200109A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| MX2016000611A (es) | Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor. | |
| CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
| UY35478A (es) | PROTEÍNAS DE UNIÓN ESPECÍFICAS DUALES DIRIGIDAS CONTRA IL-1ß y/o IL-17 | |
| MX2016002166A (es) | Anticuerpos. | |
| BR112016010822A2 (pt) | anticorpos específicos para fcrn | |
| CR20150585A (es) | Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares | |
| CL2018000298A1 (es) | Anticuerpos anti-cd154 y métodos de uso de estos. | |
| BR112018075222A2 (pt) | anticorpos anti-tnfrsf25 | |
| PE20151774A1 (es) | Construcciones de proteinas mitocondriales y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |